Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]

  • In development
  • GID-TA11638
  • Expected publication date: 

Suggested remit: To appraise the clinical and cost effectiveness of Lenacapavir within its marketing authorisation for preventing HIV infection